Active Ingredient History
Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA. Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 3)
Adenocarcinoma, Clear Cell (Phase 3)
Adenocarcinoma, Mucinous (Phase 3)
Adolescent (Phase 2)
Amyloidosis (Phase 2)
Androgens (Phase 1)
Angiogenesis Modulating Agents (Phase 2)
Anterior Cruciate Ligament Injuries (Phase 2)
Antimetabolites, Antineoplastic (Phase 3)
Antineoplastic Agents (Phase 2)
Anxiety Disorders (Phase 2)
Astrocytoma (Phase 1)
Bile Duct Neoplasms (Phase 3)
Biliary Tract Diseases (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Biomarkers (Phase 2)
Bone Marrow Diseases (Phase 2)
Bone Neoplasms (Phase 1/Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 1)
Breast Neoplasms, Male (Phase 2)
Brenner Tumor (Phase 3)
Bronchial Diseases (Phase 3)
Bronchial Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 2)
Cachexia (Phase 2)
Carboplatin (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Bronchogenic (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma in Situ (Phase 2/Phase 3)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinoma, Pancreatic Ductal (Phase 3)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Small Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 4)
Central Nervous System Neoplasms (Phase 2)
Chemoradiotherapy (Phase 3)
Child (Phase 2)
Cholangiocarcinoma (Phase 4)
Cholestasis (Phase 1)
Chondrosarcoma (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Circulating Tumor DNA (Phase 2)
Cisplatin (Phase 2)
Clonal Hematopoiesis (Phase 2)
Colitis, Ulcerative (Phase 1/Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Cyclophosphamide (Phase 2)
Cystectomy (Phase 4)
Cytoreduction Surgical Procedures (Phase 2)
Depression (Phase 2)
Dexamethasone (Phase 2)
Diffuse Intrinsic Pontine Glioma (Early Phase 1)
Digestive System Diseases (Phase 3)
Digestive System Neoplasms (Phase 3)
Disease-Free Survival (Phase 2/Phase 3)
Disease Progression (Phase 2)
Drug Evaluation (Phase 2)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Drug Therapy, Combination (Phase 2)
Endocrine Gland Neoplasms (Phase 3)
Endocrine System Diseases (Phase 3)
Endometrial Neoplasms (Phase 2)
Endoscopic Ultrasound-Guided Fine Needle Aspiration (Phase 2/Phase 3)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Ependymoma (Phase 1)
Epidermal Growth Factor (Phase 2)
Epstein-Barr Virus Infections (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Fatigue (Phase 2)
Fibrosarcoma (Phase 2)
Gallbladder Neoplasms (Phase 3)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
General Surgery (Phase 3)
Genes, erbB-2 (Phase 3)
Genital Neoplasms, Female (Phase 3)
Genital Neoplasms, Male (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1/Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 3)
Hemangioendothelioma (Phase 2)
Hemangiosarcoma (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)
Hepatoblastoma (Phase 3)
Hernia (Phase 3)
Histiocytoma (Phase 2)
Histone Deacetylase Inhibitors (Phase 2)
Hodgkin Disease (Phase 3)
Immune Checkpoint Inhibitors (Phase 2/Phase 3)
Immune System Diseases (Phase 2)
Immunoproliferative Disorders (Phase 2)
Immunotherapy (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 2)
Kidney Neoplasms (Phase 2)
Klatskin Tumor (Phase 3)
Lapatinib (Phase 2)
Laryngeal Neoplasms (Phase 2)
Leiomyosarcoma (Phase 3)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Leydig Cell Tumor (Phase 1)
Liposarcoma (Phase 2)
Liver (Phase 1)
Liver Cirrhosis (Phase 3)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 3)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 3)
Lymphatic Diseases (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 4)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 4)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 3)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 4)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Meningioma (Phase 1)
Meningitis (Phase 1)
Mesothelioma (Phase 3)
Mesothelioma, Malignant (Phase 3)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 3)
Mycosis Fungoides (Phase 2)
Myeloproliferative Disorders (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Diseases (Phase 3)
Nasopharyngeal Neoplasms (Phase 3)
Neoadjuvant Therapy (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasm Recurrence, Local (Phase 3)
Neoplasms ()
Neoplasms by Histologic Type (Phase 3)
Neoplasms by Site (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplasms, Glandular and Epithelial (Phase 1/Phase 2)
Neoplasms, Nerve Tissue (Phase 3)
Neoplasms, Neuroepithelial (Phase 1)
Neoplasms, Unknown Primary (Phase 3)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors, Primitive (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibrosarcoma (Phase 1/Phase 2)
Oligodendroglioma (Phase 1)
Oncogene Proteins (Phase 2)
Oncogenes (Phase 1)
Oropharyngeal Neoplasms (Phase 2)
Osteosarcoma (Phase 2/Phase 3)
Ovarian Diseases (Phase 3)
Oxaliplatin (Phase 2)
Pain (Phase 2)
Pancreatic Cyst (Phase 2/Phase 3)
Pancreatic Diseases (Phase 3)
Pancreatic Intraductal Neoplasms (Phase 3)
Paraganglioma (Phase 1)
Pediatrics (Phase 3)
Pelvic Neoplasms (Phase 3)
Penile Neoplasms (Phase 1)
Peritoneal Cavity (Phase 2)
Peritoneal Neoplasms (Phase 3)
Pinealoma (Phase 1)
Plasmacytoma (Phase 2)
Pleural Effusion, Malignant (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Early Phase 1)
Prostatic Neoplasms (Phase 3)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Proto-Oncogene Proteins p21(ras) (Phase 1/Phase 2)
Pseudomyxoma Peritonei (Phase 1)
Radiation Oncology (Phase 2)
Radiotherapy (Phase 3)
Receptors, Fibroblast Growth Factor (Phase 3)
Rectal Neoplasms (Phase 1/Phase 2)
Recurrence (Phase 3)
Respiratory Tract Diseases (Phase 3)
Respiratory Tract Neoplasms (Phase 3)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 2)
Rituximab (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Sepsis (Phase 2)
Sezary Syndrome (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Survival (Phase 2/Phase 3)
Testicular Neoplasms (Phase 2)
Therapeutics (Phase 1/Phase 2)
Thoracic Neoplasms (Phase 3)
Thrombocytopenia (Phase 2)
Thromboembolism (Phase 3)
Thyroid Neoplasms (Phase 2)
Treatment Refusal (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Ureteral Diseases (Phase 1)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 3)
Urinary Bladder (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
